NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Study in Portuguese Hospitals to Describe Patient Characteristics, Treatment Patterns and Outcomes

CompletedN/A

Sponsor: AstraZeneca

Conditions: Severe Asthma

Countries: Portugal

Benralizumab is indicated as an add-on maintenance treatment in adult patients with severe eosinophilic asthma inadequately controlled despite high-dose inhaled corticosteroids plus long-acting β2-agonists. It has been reimbursed in Portugal as an add-on therapy since May 2019. In order of this, there is crucial need in Portugal to provide key real-word evidence on benralizumab therapy.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* Adults patients with severe asthma treated with benralizumab, who had their first benralizumab dose between July 2019 and October 2020

  * Patients who have at least 1 benralizumab injection and with at least 3 months follow-up data from the first injection.
  * Give voluntary signed informed consent

Exclusion Criteria:

* Currently receiving benralizumab or any other biologic drug for the treatment of asthma in a clinical trial

Locations (16)

Amadora, Portugal
Barcelos, Portugal
Coimbra, Portugal
Coimbra, Portugal
Faro, Portugal
Leiria, Portugal
Lisbon, Portugal
Lisbon, Portugal
Matosinhos Municipality, Portugal
Portimão, Portugal
Porto, Portugal
Porto, Portugal
Porto, Portugal
Santarém, Portugal
Vila Nova de Gaia, Portugal
Vila Real, Portugal